Study of a third-line drug combo for advanced duodenal cancer
Part of Cancer clinical trials.
This trial tests whether furquinitinib plus sintilimab works better for advanced duodenal adenocarcinoma after prior treatments. It aims to slow or shrink the cancer, especially when surgery isn’t possible and the cancer has come back or spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- Your duodenal adenocarcinoma is advanced and not removable by surgery, or it has returned or spread.
- A biopsy (tissue sample) confirmed the duodenal adenocarcinoma.
- You are well enough for treatment (ECOG 0–2, meaning you can do most daily activities).
- You have at least one measurable or trackable spot on scans.
- You are seeking treatment that is third-line or later using sintilimab plus furquinitinib (you’ve had earlier cancer treatments already).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three new drugs (S-531011, fruquintinib, and possibly pembrolizumab) to treat advanced colorectal cancer that has spread and stopped responding to standard chemotherapy. The trial is designed to see if this combination is safe and effective for patients whose tumors have a specific genetic profile.
This trial tests a combination of two drugs – fruquintinib (a pill that targets blood vessels feeding tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer) – for people with advanced endometrial cancer that has already been treated with platinum chemotherapy. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial is testing a combination of two oral anti-cancer drugs (fruquintinib and S-1) for people whose metastatic colorectal cancer has not responded to at least two standard treatments. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
Hear when a new Third-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.